Traders should monitor for potential arbitrage opportunities between the current stock price and the $16.50 offer price, while watching for regulatory approval timelines and any competing bids. The significant insider rollover suggests strong confidence in the company's future prospects under private ownership.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 3 $16.26entry
- T+1 · 9mo ago −0.06%α −0.82% · $16.25
- T+5 · 8mo ago 0.00%α +0.48% · $16.26
- T+20 · 8mo ago +0.18%α +4.59% · $16.29
- T+60 · 6mo ago +1.54%α −8.78% · $16.51
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Select Medical Holdings Corporation (SEM) has agreed to be acquired by a consortium led by its Executive Chairman Robert A. Ortenzio, Senior Executive Vice President Martin F. Jackson, and private equity firm Welsh, Carson, Anderson & Stowe (WCAS) for $16.50 per share in cash, representing a total enterprise value of $3.9 billion. The transaction, approved by a special committee of independent directors, will take SEM private and is expected to close in mid-2026 subject to shareholder and regulatory approvals.
Key Facts
- All-in cash offer of $16.50 per share, representing an 18% premium to SEM's unaffected share price as of November 24, 2025, and a 25% premium to its 90-day volume-weighted average price
- Total enterprise value of $3.9 billion
- Transaction to be financed through committed debt and equity financing, with no financing condition
- Key insiders (Ortenzio, Jackson, and WCAS) holding ~11.8% of shares will roll over their equity into the new entity
- Expected closing in mid-2026, subject to shareholder approval (excluding insiders), regulatory approvals including HSR, and other customary conditions
- If terminated under certain circumstances, SEM would pay a termination fee of $66.5 million, while the buyer would pay $133 million if they fail to close after conditions are satisfied
Financial Impact
Cash consideration of $16.50 per share for all outstanding shares not rolled over, with a total enterprise value of $3.9 billion
Risk Factors
- Failure to obtain required shareholder or regulatory approvals
- Potential for competing bids that could increase the offer price
- Integration risks if the deal closes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-022581 |
| Document: tm267827d2_defa14a.htm | 0001104659-26-022581 |
| Document: tm267827d2_ex99-1.htm | 0001104659-26-022581 |
| Document: 0001104659-26-022581-index-headers.html | 0001104659-26-022581 |
| Document: 0001104659-26-022581-index.html | 0001104659-26-022581 |
| Document: 0001104659-26-022581.txt | 0001104659-26-022581 |
Track record
8 reports on SEM
The track record builds as more bullish or bearish reports settle.
Filters
- Jul 13, 202618w ago 15-12G Neutral 4/10 No price data
- Jul 1, 202619w ago 25-NSE Neutral 9/10 Entry $16.52 No price data
- Jul 1, 202619w ago 8-K Bullish 8/10 Entry $16.52 No price data
- Jun 26, 202620w ago 8-K Bullish 7/10 Entry $16.53 No price data
- Apr 30, 202628w ago 8-K Bearish 6/10 Entry $16.38 to $16.51 ▼ −0.81% +4.45% vs SPY
- Apr 15, 202630w ago PREM14A Bullish 8/10 Entry $16.38 to $16.45 ▲ +0.43% −5.62% vs SPY
- Mar 4, 202636w ago DEFA14A Neutral 3/10 Entry $16.25 to $16.29 ▲ +0.25% +4.66% vs SPY
- Mar 3, 202636w ago DEFA14A Bullish 9/10 Viewing Entry $16.26 to $16.29 ▲ +0.18% +4.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers